A centralized system for monitoring clozapine use in British Columbia

Psychiatric Services

Volumn 47, Issue 1, 1996, Pages 81-83

  Black, Lori L ^a   Greenidge, Lori L ^a   Ehmann, Tom ^a   Ganesan, Soma ^a   Honer, William G ^a  

^a RIVERVIEW HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADULT; AGRANULOCYTOSIS; ARTICLE; CLINICAL PRACTICE; DOSE RESPONSE; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT MONITORING; RISK ASSESSMENT; SCHIZOPHRENIA;

EID: 0030021537     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.47.1.81     Document Type: Article

References (7)

1. Product Monograph for Clozaril (Clozapine Tablets). Dorval. Quebec. Sandoz Canada 1991
2. Reid W, Pham V. Rago W: Clozapine use by state programs: public mental health programs respond to a new medication. Hospital and Community Psychiatry 44:739-743, 1993
3. Krupp E Barnes P: Clozapine-associated agranulocytosis: risk and etiology. British Journal of Psychiatry 160(suppl 17):38-40, 1992
4. Alvir J, Lieberman J, Sofferman J. et al: Clozapine-induced agranulocytosis: incidence and risk factors in the United States. New England Journal of Medicine 329: 162-167, 1993
5. Lieberman JA, Alvir J, Ma J: A report of clozapine-induced agranulocytosis in the United States: incidence and risk factors. Drug Safety 9(suppl 1):1-2, 1992
6. Hummer M, Kurz M, Barnas C, et al: Transient neutropenia induced by clozapine Psychopharmacology Bulletin 28:287-290, 1992
7. Torrey EF, Bigelow DA, Sladen-Dew N. Quality and cost of services for seriously mentally ill individuals in British Columbia and the United States. Hospital and Community Psychiatry 44:943-950, 1993